Loading...
Loading...
India's semaglutide imports from UNITED STATES total $6.4M across 268 shipments from 15 foreign suppliers. ESPEE BIOPHARMA & FINECHEM LLC leads with $2.1M in import value; the top 5 suppliers together control 54.4% of this origin. Leading Indian buyers include CIPLA LIMITED. This corridor reflects India's pharmaceutical import demand for semaglutide โ a diversified sourcing base with multiple active suppliers from UNITED STATES.

ESPEE BIOPHARMA & FINECHEM LLC is the leading Semaglutide supplier from UNITED STATES to India, with import value of $2.1M across 39 shipments. The top 5 suppliers โ ESPEE BIOPHARMA & FINECHEM LLC, M/S. ADIRAMEDICA LLC, Pharmaceutical Buyers, Inc., M/S SUN PHARMACEUTICAL INDUSTRIES INC, ESPEE BIOPHARMA & FINECHEM LLC. โ collectively account for 54.4% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ESPEE BIOPHARMA & FINECHEM LLC | $2.1M | 39 | 33.1% |
| 2 | M/S. ADIRAMEDICA LLC | $368.3K | 3 | 5.7% |
| 3 | Pharmaceutical Buyers, Inc. | $357.9K | 13 | 5.6% |
| 4 | M/S SUN PHARMACEUTICAL INDUSTRIES INC | $320.1K | 7 | 5.0% |
| 5 | ESPEE BIOPHARMA & FINECHEM LLC. | $317.6K | 8 | 5.0% |
| 6 | M S ESPEE BIOPHARMA FINECHEM LLC | $298.7K | 1 | 4.7% |
| 7 | Espee Biopharma & Finechem LLC | $284.6K | 14 | 4.4% |
| 8 | M/S. PHARMACEUTICAL BUYERS, INC. | $283.2K | 7 | 4.4% |
| 9 | AGRACE PHARMA | $277.0K | 35 | 4.3% |
| 10 | REGIONAL PHARMACY | $243.7K | 8 | 3.8% |
| 11 | ESPEE BIOPHARMA FINECHEM LLC | $210.5K | 9 | 3.3% |
| 12 | M/S. SUN PHARMACEUTICAL INDUSTRIES | $165.4K | 14 | 2.6% |
| 13 | RAFF & HALL PHARMACY, | $155.2K | 6 | 2.4% |
| 14 | Raff & Hall Pharmacy | $121.1K | 6 | 1.9% |
| 15 | AGRACE PHARMA. | $116.2K | 10 | 1.8% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | CIPLA LIMITED | $1.8M | 3 | 27.4% |
| 2 | NATCO PHARMA LIMITED | $793.0K | 17 | 12.4% |
| 3 | MSN LABORATORIES PRIVATE LIMITED | $570.1K | 10 | 8.9% |
| 4 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $526.3K | 23 | 8.2% |
| 5 | ZYDUS LIFESCIENCES LIMITED | $519.1K | 18 | 8.1% |
| 6 | DR.REDDY'S LABORATORIES LTD | $459.2K | 18 | 7.2% |
| 7 | MYLAN LABORATORIES LIMITED | $395.0K | 16 | 6.2% |
| 8 | ALKEM LABORATORIES LIMITED | $306.6K | 5 | 4.8% |
| 9 | ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMI | $225.2K | 33 | 3.5% |
| 10 | STERISCIENCE SPECIALTIES PRIVATE LIMITED | $190.3K | 8 | 3.0% |
| 11 | AUROBINDO PHARMA LTD | $121.6K | 11 | 1.9% |
| 12 | HETERO LABS LIMITED | $94.4K | 6 | 1.5% |
| 13 | EUGIA PHARMA SPECIALITIES LIMITED | $65.0K | 4 | 1.0% |
| 14 | CADILA HEALTHCARE LIMITED | $63.1K | 3 | 1.0% |
| 15 | LUPIN LIMITED | $53.3K | 8 | 0.8% |
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Semaglutide suppliers from UNITED STATES to India include ESPEE BIOPHARMA & FINECHEM LLC, M/S. ADIRAMEDICA LLC, Pharmaceutical Buyers, Inc.. The leading supplier is ESPEE BIOPHARMA & FINECHEM LLC with import value of $2.1M USD across 39 shipments. India imported Semaglutide worth $6.4M USD from UNITED STATES in total across 268 shipments.
India imported Semaglutide worth $6.4M USD from UNITED STATES across 268 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Semaglutide sourced from UNITED STATES include CIPLA LIMITED, NATCO PHARMA LIMITED, MSN LABORATORIES PRIVATE LIMITED. The largest buyer is CIPLA LIMITED with $1.8M in imports across 3 shipments.
The total value of Semaglutide imports from UNITED STATES to India is $6.4M USD, across 268 shipments and 15 foreign suppliers. Data source: Indian Customs (DGFT).
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
268 Verified Shipments
15 suppliers, 15 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists